Amicus Therapeutics – 2025-12-19 - increase Confidence 9/10

FOLD – increase in Days/Weeks

Amicus Therapeutics reported 18% year-over-year revenue growth in Q2 2025, driven by strong uptake of Pombiliti + Opfolda, amid a definitive acquisition agreement from BioMarin at $14.50 per share. This offer represents a 2.25% immediate upside from the current trading price of $14.18.

Why This Matters

The combination of accelerating revenue growth, resolution of U.S. patent litigation extending Galafold exclusivity to 2037, and a fully financed all-cash acquisition creates a highly supportive near-term price environment. With the deal unanimously approved by both boards and expected to close in Q2 2026, the stock is likely to trade closer to the $14.50 offer price in the absence of regulatory or antitrust complications—particularly as no financing condition is attached to the transaction.

Key Insights

• Revenue Growth: Q2 2025 total revenue of $154.7M, up 18% YoY, with Pombiliti + Opfolda surging 58%
• News Impact: BioMarin’s $14.50/share all-cash offer (2.25% above current price) sets a near-term price ceiling and catalyst for arbitrage tightening
• Risk/Offset: Shareholder lawsuit investigation by Halper Sadeh LLC could delay but not likely derail the deal

Practical Implications

• Bull Case: Deal momentum and strong product revenue drive price to $14.50 within weeks; potential for slight bump if competing bids emerge
• Bear Case: Regulatory scrutiny or lawsuit escalation could create short-term volatility, but low probability of deal collapse
• Confidence: 9/10 – All-cash, unconditionally approved acquisition with near-term closure window

Prediction: increase

Reference:

• https://finance.yahoo.com/news/biomarin-acquire-amicus-therapeutics-4-124500714.html
• https://stockanalysis.com/stocks/fold/
• https://www.businesswire.com/news/home/20251219512883/en/